Inhibition of Calcification on an Endovascular Device

• US 20070237802A1
• Filed: 04/11/2006
• Published: 10/11/2007
• Est. Priority Date: 04/11/2006
• Status: Abandoned Application

• Current Assignee: Medtronic Vascular, Inc. (Medtronic Plc)
• Original Assignee: Medtronic Vascular, Inc. (Medtronic Plc)
• Inventors: McKay, William
• Application Number:
  US11/279,325
• Publication Number:
  US 20070237802A1
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61L 2300/436 of receptors
• CPC Class Codes: A61L 2400/02 Treatment of implants to prevent calcification or mineralisation in vivo
• CPC Class Codes: A61L 27/507 for artificial blood vessels apparatus for applying cells on a blood vessel prosthesis A61F2/062
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

An endovascular device includes a body having a surface, and at least one protein or peptide antagonist of calcification disposed on a portion of the surface. In another embodiment of the invention, an endoluminal device includes a body having a surface, and a coating disposed on a portion of the surface. The coating includes a transforming growth factor beta receptor antagonist. Another embodiment of the invention provides a method of inhibiting calcification of an endoluminal device. The method includes providing a body including a surface, disposing at least one protein or peptide antagonist of calcification on a portion of the surface, and deploying the body at a treatment site.

Claims

1. An endovascular device comprising:

a body including a surface; and

at least one protein or peptide antagonist of calcification disposed on a portion of the surface, wherein the at least one protein or peptide antagonist comprises at least one transforming growth factor beta receptor antagonist.

4. The device of claim 1 wherein the at least one transforming growth factor beta receptor antagonist comprises at least one bone morphogenic protein receptor antagonist.

5. The device of claim 1 wherein the at least one transforming growth factor beta receptor antagonist comprises at least one growth differentiation factor receptor antagonist.

6. The device of claim 4 wherein the at least one bone morphogenic protein receptor antagonist is selected from the group consisting of chordin, sclerostin, and noggin.

7. The device of claim 1 wherein the at least one transforming growth factor beta receptor antagonist comprises a cytokine.

8. The device of claim 1 wherein the body is selected from a group consisting of a stent, a valve prosthesis, a vascular graft, and a stent-graft.

9. The device of claim 1 wherein the body is biodegradable.

10. The device of claim 1 wherein the at least one protein antagonist is integrated in a natural polymer.

11. The device of claim 10 wherein the natural polymer is chosen from the group consisting of collagen polymer, polysaccharides, elastin, silk and hyluronic acid.

2. (canceled)

3. (canceled)

12. An endoluminal device comprising:

a body including a surface; and

a coating disposed on a portion of the surface;

wherein the coating comprises a transforming growth factor beta receptor antagonist.

13. The device of claim 12 wherein the at least one transforming growth factor beta receptor antagonist comprises at least one bone morphogenic protein receptor antagonist.

14. The device of claim 12 wherein the at least one transforming growth factor beta receptor antagonist comprises at least one growth differentiation factor receptor antagonist.

15. The device of claim 12 wherein the body is selected from a group consisting of a stent, a valve prosthesis, a vascular graft, and a stent-graft.

16. The device of claim 12 wherein the body is biodegradable.

17. The device of claim 12 wherein the at least one protein or peptide antagonist is integrated in a natural polymer.

18. The device of claim 17 wherein the natural polymer is chosen from the group consisting of collagen polymer, polysaccharides, elastin, silk and hyluronic acid.

19. A method of inhibiting calcification of an endoluminal device, the method comprising:

providing a body including a surface;

disposing at least one protein or peptide antagonist of calcification on a portion of the surface; and

deploying the body at a treatment site.

20. The method of claim 19 further comprising inhibiting at least one bone morphogenic protein receptor.

21. The method of claim 19 further comprising inhibiting at least one growth differentiation factor receptor.

22. The method of claim 19 further comprising biodegrading the body.